Post job

Aptevo Therapeutics CEO and executives

Executive Summary. Based on our data team's research, Marvin L. White is the Aptevo Therapeutics's CEO. Aptevo Therapeutics has 58 employees, of which 12 are in a leadership position.
Here are further demographic highlights of the leadership team:
  • The Aptevo Therapeutics executive team is 33% female and 67% male.
  • 48% of the management team is White.
  • 10% of Aptevo Therapeutics management is Hispanic or Latino.
  • 15% of the management team is Black or African American.
Work at Aptevo Therapeutics?
Share your experience

Rate Aptevo Therapeutics' leaders' effectiveness in guiding the company.

Zippia waving zebra
Name & TitleBio
Marvin L. White

President/CEO

Marvin L. White's LinkedIn

Mr. White leads Aptevo Therapeutics as the President and Chief Executive Officer. Prior to this role he was a member of Emergent BioSolutions’ Board of Directors. He is the former Chief Financial Officer of St. Vincent’s Health, a $2.8 billion multi-hospital health system. Mr. White previously served as Executive Director and CFO of Lilly USA, a subsidiary of Eli Lilly and Company, and held other positions in corporate finance at Eli Lilly and Company. He serves on the boards WP Glimcher and OneAmerica Financial Partners Inc., and was previously on the board of of CoLucid Pharmaceuticals, Inc.

Jeffrey G. Lamothe

EVP and Chief Financial Officer

Jeffrey G. Lamothe's LinkedIn

Mr. Lamothe leads Finance, Business Development, Investor Relations, and IT. Prior to Aptevo Therapeutics, he was Emergent’s VP Finance, Biosciences Division. Mr. Lamothe assumed this role in 2014 when Emergent concluded the acquisition of Cangene Corporation, where he was Chief Financial Officer. Mr. Lamothe’s business experience is built on a 25+ year career, spanning several industries and both CFO and CEO roles. Prior to Cangene Corporation, Mr. Lamothe was the Chief Financial Officer for Smith Carter Architects and Engineers Incorporated. He also previously served as President and Chief Executive Officer of Kitchen Craft Cabinetry after occupying the position of VP Finance and Chief Financial Officer with that organization. Mr. Lamothe’s other past experience includes serving as Chief Financial Officer for Motor Coach Industries and he has held various roles at James Richardson & Sons, Limited and Ernst & Young LLP.

Daniel J. Abdun-Nabi

Board Member

Daniel J. Abdun-Nabi's LinkedIn

Jane Gross Ph.d

Senior Vice President and CSO

Jane Gross Ph.d's LinkedIn

Jane Gross is a Senior VP/Chief Scientific Ofcr at APTEVO THERAPEUTICS INC. and Board Member at aTyr Pharma Inc. She studied at University of California.

John E. Niederhuber

Chairman

John E. Niederhuber's LinkedIn

Barbara Lopez Kunz

Board Member

Barbara Lopez Kunz's LinkedIn

Grady Grant

Board Member

Grady Grant's LinkedIn

So Young Kwon

SVP, General Counsel

So Young Kwon's LinkedIn

Zsolt Pál Harsányi

Board Member

Zsolt Pál Harsányi's LinkedIn

Daphne L. Taylor

Vice President Finance

Daphne L. Taylor's LinkedIn

Do you work at Aptevo Therapeutics?

Does leadership effectively guide Aptevo Therapeutics toward its goals?

Aptevo Therapeutics jobs

Aptevo Therapeutics founders

Name & TitleBio
Marvin L. White

President/CEO

Marvin L. White's LinkedIn

Mr. White leads Aptevo Therapeutics as the President and Chief Executive Officer. Prior to this role he was a member of Emergent BioSolutions’ Board of Directors. He is the former Chief Financial Officer of St. Vincent’s Health, a $2.8 billion multi-hospital health system. Mr. White previously served as Executive Director and CFO of Lilly USA, a subsidiary of Eli Lilly and Company, and held other positions in corporate finance at Eli Lilly and Company. He serves on the boards WP Glimcher and OneAmerica Financial Partners Inc., and was previously on the board of of CoLucid Pharmaceuticals, Inc.

Aptevo Therapeutics board members

Name & TitleBio
Marvin L. White

President/CEO

Marvin L. White's LinkedIn

Mr. White leads Aptevo Therapeutics as the President and Chief Executive Officer. Prior to this role he was a member of Emergent BioSolutions’ Board of Directors. He is the former Chief Financial Officer of St. Vincent’s Health, a $2.8 billion multi-hospital health system. Mr. White previously served as Executive Director and CFO of Lilly USA, a subsidiary of Eli Lilly and Company, and held other positions in corporate finance at Eli Lilly and Company. He serves on the boards WP Glimcher and OneAmerica Financial Partners Inc., and was previously on the board of of CoLucid Pharmaceuticals, Inc.

Daniel J. Abdun-Nabi

Board Member

Daniel J. Abdun-Nabi's LinkedIn

John E. Niederhuber

Chairman

John E. Niederhuber's LinkedIn

Barbara Lopez Kunz

Board Member

Barbara Lopez Kunz's LinkedIn

Grady Grant

Board Member

Grady Grant's LinkedIn

Zsolt Pál Harsányi

Board Member

Zsolt Pál Harsányi's LinkedIn

Fuad Hibri

Board Member

Aptevo Therapeutics executives FAQs

Zippia gives an in-depth look into the details of Aptevo Therapeutics, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Aptevo Therapeutics. The employee data is based on information from people who have self-reported their past or current employments at Aptevo Therapeutics. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Aptevo Therapeutics. The data presented on this page does not represent the view of Aptevo Therapeutics and its employees or that of Zippia.

Aptevo Therapeutics may also be known as or be related to APTEVO THERAPEUTICS INC., Aptevo Therapeutics, Aptevo Therapeutics Inc, Aptevo Therapeutics Inc. and Aptevo Therapeutics, Inc.